NCT06537505Not yet recruitingPhase 2
An Exploratory Clinical Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Advanced Second-line and Above Solid Tumors
Beidahuang Industry Group General Hospital0 sites60 target enrollmentStarted: August 5, 2024Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Primary Endpoint
- Objective Response Rate
Study Overview
Brief Summary
This is a multi-center, phase Il trial to evaluate the efficacy and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs in the treatment of advanced second-line and above solid tumors.
Detailed Description
This study plans to recruit 60 patients witha dvanced second-line and above solid tumors observe and evaluate the effectiveness and safety of microwave ablation combined with immunotherapy ± anti-angiogenic drugs.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients with clinically confirmed advanced non-small cell lung cancer or hepatocellular carcinoma;
- •Previously received systemic treatment;
- •Expected survival period > 3 months;
- •Age: 18-75 years old, male or female;
- •ECOG PS: 0-2 points;
- •The function of important organs meets the following requirements: a) Absolute neutrophil count ≥1.5×109/L, platelet ≥90×109/L, hemoglobin ≥90g/dL; b) Bilirubin ≤3 times ULN (patients drained by retrograde technique can be included); ALT and AST ≤5 times ULN, albumin>35g/ml, prothrombin time prolonged <6 seconds; c) Creatinine <120 μmol/L, or MDRD creatinine clearance >60 mL/min;
- •Women of childbearing age must have a negative pregnancy test (βHCG) before starting treatment, and women of childbearing age and men (having sexual relations with women of childbearing age) must agree to use effective contraceptive measures uninterruptedly during treatment and for 6 months after the last treatment dose;
- •The patient voluntarily joined this study and signed the informed consent form.
Exclusion Criteria
- •Patients who have had other malignant tumors in the past or at the same time within 5 years, but excluding cured basal cell carcinoma of the skin, cervical carcinoma in situ, superficial or non-invasive bladder cancer, etc.
- •Patients with severe bleeding tendency and coagulation dysfunction that cannot be corrected in the short term;
- •Patients with severe pulmonary fibrosis and pulmonary hypertension;
- •Patients with infectious and radioactive inflammation around the lesion and skin infection at the puncture site that is not well controlled;
- •Systemic infection, high fever >38.5 ℃;
- •Severe anemia, dehydration and severe nutritional metabolism disorder that cannot be corrected or improved in a short period of time;
- •Poorly controlled malignant pleural effusion;
- •Uncontrolled, symptomatic brain metastasis or a history of difficult-to-control mental illness or severe intellectual or cognitive impairment;
- •Subjects with active, known or suspected autoimmune diseases, hypothyroidism that only requires hormone replacement therapy, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia) can be selected;
- •Congestive heart failure, uncontrollable arrhythmias, myocardial infarction within 6 months, unstable angina, stroke or transient ischemic attack;
- •Patients who cannot comply with the trial protocol or cannot cooperate with follow-up;
- •History of psychotropic drug abuse, alcoholism or drug abuse;
- •Human immunodeficiency virus (HIV, HIV 1/2 antibody) positive;
- •Those who are considered by the researchers to be unsuitable for participation in this trial.
Arms & Interventions
microwave ablation combined with immunotherapy and anti-angiogenic drugs
Experimental
microwave ablation combined with adebrelimab and apatinib
Intervention: Adebrelimab (Drug)
microwave ablation combined with immunotherapy and anti-angiogenic drugs
Experimental
microwave ablation combined with adebrelimab and apatinib
Intervention: Apatinib (Drug)
microwave ablation combined with immunotherapy and anti-angiogenic drugs
Experimental
microwave ablation combined with adebrelimab and apatinib
Intervention: microwave ablation (Procedure)
microwave ablation combined with immunotherapy
Experimental
microwave ablation combined with adebrelimab
Intervention: Adebrelimab (Drug)
microwave ablation combined with immunotherapy
Experimental
microwave ablation combined with adebrelimab
Intervention: microwave ablation (Procedure)
Outcomes
Primary Outcomes
Objective Response Rate
Time Frame: up to 24 months
Determined using RECIST V1.1 criteria, defined as best overall response (CR or PR)
Secondary Outcomes
- incidence rate of AE(up to 36 months)
- Overall Survival(up to 36 months)
- Disease control rate(up to 24 months)
- Progression-free Survival(up to 36 months)
Investigators
LiuMingyang
Associate Chief Physician
Beidahuang Industry Group General Hospital
Similar Trials
Recruiting
Phase 2
Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical TrialMultiple Primary Lung CancerNCT05053802Shanghai Pulmonary Hospital, Shanghai, China146
Recruiting
Not Applicable
Microwave Ablation for LeiomyomaUterine FibroidNCT04240262Karolinska Institutet200
Completed
Phase 1
Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.Bone TumorRenal TumorLung TumorNCT02862288Centre Hospitalier Universitaire de Besancon30
Unknown
Not Applicable
Microwave vs. Radiofrequency Ablation for Benign Thyroid Nodules: A Multicenter Randomized Controlled Trial StudyBenign Thyroid NodulesAblationNCT04046354Chinese PLA General Hospital149
Completed
Not Applicable
Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency AblationThermoablationChronic Liver DiseaseHepatocellular CarcinomaNCT02859753Centre Hospitalier Universitaire Dijon35